Navigation Links
Study identifies key player in motor neuron death in Lou Gehrig's disease
Date:3/26/2014

Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is marked by a cascade of cellular and inflammatory events that weakens and kills vital motor neurons in the brain and spinal cord. The process is complex, involving cells that ordinarily protect the neurons from harm. Now, a new study by scientists in The Research Institute at Nationwide Children's Hospital points to a potential culprit in this good-cell-gone-bad scenario, a key step toward the ultimate goal of developing a treatment.

Motor neurons, or nerve cells, in the brain and spinal cord control the function of muscles throughout the body. In amyotrophic lateral sclerosis (ALS), motor neurons die and muscles weaken. Patients gradually lose the ability to move and as the disease progresses, are unable to breathe on their own. Most people with ALS die from respiratory failure within 3 to 5 years from the onset of symptoms.

For the study, published online this month in Neuron, researchers examined a protein involved in transcriptional regulation, called nuclear factor-kappa B (NF-κB), known to play a role in the neuroinflammatory response common in ALS. NF-ƘB has also been linked to cancer and a number of other inflammatory and autoimmune diseases.

Using animal models, the researchers studied disease progression in mice in which NF-ƘB had been inhibited in two different cell types astrocytes, the most abundant cell type in the human brain and supporters of neuronal function; and microglia, macrophages in the brain and spinal cord that act as the first and main form of defense against invading pathogens in the central nervous system. Inhibiting NF-ƘB in microglia in mice slowed disease progression by 47 percent, says Brian Kaspar, MD, a principal investigator in the Center for Gene Therapy at Nationwide Children's and senior author of the new study.

"The field has identified different cell types in addition to motor neurons involved in this disease, so one of our approaches was to find out what weapons these cells might be using to kill motor neurons," Dr. Kaspar says. "And our findings suggest that the microglia utilize an NF-κB-mediated inflammatory response as one of its weapons."

Inhibiting the protein in astrocytes had no impact on disease progression, so the search for the weapons that cell type uses against motor neurons continues. These preliminary findings also don't tell scientists how or why NF-κB turns the ordinarily protective microglia into neuron-killing molecules. But despite the mysteries that remain, the study moves scientists closer to finding a treatment for ALS.

The search for an ALS therapy has been focused in two directions: identifying the trigger that leads to disease onset and understanding the process that leads to disease progression. Changes in motor neurons are involved in disease onset, but disease progression seems to be dictated by changes to astrocytes, microglia and oligodendrocytes. Some cases of ALS are hereditary but the vast majority of patients have no family ties to the disease. The complexity of the disease and the lack of a clear familiar tie make screening before disease onset nearly impossible, highlighting the importance of slowing the disease, Dr. Kaspar says.

"Focusing on stopping the changes that occur in astrocytes and microglia has clinical relevance because most people don't know they're getting ALS, says Dr. Kaspar, who also is an associate professor of pediatrics and neurosciences at The Ohio State University College of Medicine. "We have identified a pathway in microglia that may be targeted to ultimately slow disease progression in ALS and are exploring potential therapeutic strategies and may have broader implications for diseases such as Alzheimer's and Parkinson's Disease amongst others."


'/>"/>

Contact: Gina Bericchia
Gina.Bericchia@NationwideChildrens.org
614-355-0487
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that ... gift was facilitated by the Pepin Family Foundation. , “We greatly appreciate this ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... result in better care, and MEDfx and the Delaware Health Information Network (DHIN) ... , As the nation’s first state-wide health information exchange, DHIN stores and shares ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews ... and other Butler products. Ken was impressed with the safety and reliability of ... the product on his show. This endorsement by Ken Matthews can be heard ...
(Date:2/18/2017)... ... February 18, 2017 , ... ... the latest information and contact points to easily connect elderly veterans of America's ... living, and elder-care funding. It also conveys material on this year's increase in ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells ... the electronic prescribing of controlled and non-controlled substances plus the ability to manage ... in the United States now accept electronic prescriptions, according to the Office of ...
Breaking Medicine News(10 mins):
(Date:2/18/2017)... , Feb. 17, 2017 Research and Markets has ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America , ... period 2015 through 2022. Also, a six-year historic analysis is provided for ...
(Date:2/17/2017)... , Feb. 17, 2017  Ethicon, Inc. today ... Inc., a privately held medical device company that ... Management System, a novel minimally invasive device for ... Torax Medical will enable Ethicon to offer patients ... laparoscopic Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... , Feb. 17, 2017 Theravance Biopharma, ... or the "Company") today announced the presentation of ... and orally administered pan-Janus kinase (JAK) inhibitor designed ... Congress of the European Crohn,s and Colitis ... reported further data from its completed Phase 1 ...
Breaking Medicine Technology: